

July 10, 2025

Notification Regarding Decisions on Matters Relating to Acquisition and Cancellation of Treasury Shares

(Acquisition of the company's own shares under the regulations of the Articles of Incorporation pursuant to Article 165, paragraph (2) of the Companies Act, and cancellation of treasury shares in accordance with the provisions of Article 178 of the Companies Act)

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu City, Saga Prefecture; President and CEO: NAKATOMI, Kazuhide) is pleased to announce that it has resolved matters relating to the acquisition of its own shares pursuant to Article 156 of the Companies Act of Japan (the Companies Act), as applied under Article 165, paragraph (3) of the Companies Act, and to the cancellation of treasury shares in accordance with the provisions of Article 178 of the Companies Act at the meeting of the board of directors held today. The details are as follows:

1. Reasons for acquiring and canceling the company's own shares

To enhance sustainable value for the company and its shareholders, we have formulated a Basic Policy on Cash Allocation*. We aim to implement shareholder returns exceeding 50 billion yen (including dividends and share buybacks) over a five-year period, from the fiscal year ending February 2027 to the fiscal year ending February 2031. Under this policy, Hisamitsu Pharmaceutical will acquire and cancel treasury shares to strengthen shareholder returns, considering its recent performance, cash inflow forecasts, and stock market conditions.

2. Details of matters concerning the acquisition

- | | |
|---|--|
| (1) Type of shares to be acquired | Common share of Hisamitsu Pharmaceutical |
| (2) Total number of shares to be acquired | 3 million shares (Maximum) 4.09% of the total number of outstanding shares (excluding treasury shares) |
| (3) Total amount of acquisition cost | 15 billion yen (Maximum) |
| (4) Period for acquisition | From July 11, 2025 to December 31, 2025 |
| (5) Method of acquisition | (i) Acquire through an off-auction own share repurchase transaction (ToSTNeT-3) (ii) Acquire in the open market through discretionary trading on the Tokyo Stock Exchange |

3. Details of matters related to the cancellation

- | | |
|---|--|
| (1) Type of shares to be canceled | Common share of Hisamitsu Pharmaceutical |
| (2) Total number of shares to be canceled | Total number of treasury shares acquired as per Note 2 |
| (3) Scheduled date of cancellation | To be determined |

We will provide a further announcement once the acquisition of treasury shares is completed and the cancellation date is determined.

(Reference information) Status of treasury shares held as of June 30, 2025

Total number of shares issued (excluding treasury shares): 73,402,370 shares

Number of treasury shares: 1,762,525 shares

Note: The Company's shares held through Exclusive Trust for HISAMITSU PHARMACEUTICAL Employee Stockholding Partnership Plan Trust Account (350,800 shares) are not included in the number of treasury shares.

*Regarding Basic Policy on Cash Allocation

https://global.hisamitsu/pdf/news_release_E_250310.pdf

